Evoke Pharma (EVOK) Posts Smaller-than-Expected Q4 Loss
Evoke Pharma (NASDAQ: EVOK) reported Q4 EPS of ($0.02), $0.21 better than the analyst estimate of ($0.23).
Included in net loss for the fourth quarter of 2017 was a gain of approximately $2.3 million due to the change in the fair value of the warrant liability. For the year ended December 31, 2017, there was a net loss due to the change in the fair value of the warrant liability of approximately $1.0 million. The warrant liability is subject to remeasurement at each reporting period and we recognize any change in the fair value of the warrant liability in the statement of operations. We anticipate that the value of the warrants could fluctuate from quarter to quarter and that such fluctuation could have a material impact on our financial statements from quarter to quarter and year to year.
For earnings history and earnings-related data on Evoke Pharma (EVOK) click here.